RAP-219 is named as a drug or biological intervention in 4 clinical trials in our USA trial register, 3 of which are recruiting. The lead sponsor is Rapport Therapeutics Inc.. Registered phases: Phase 3 and Phase 2. Conditions studied include Epilepsy; Focal Epilepsy; Focal Seizure.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07563881 | Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1 (ClinicalTrials.gov ↗) Focal Seizure, Epilepsy, Focal Epilepsy |
Phase 3 | Recruiting |
| NCT07594119 | Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures (ClinicalTrials.gov ↗) Focal Seizure, Epilepsy, Focal Epilepsy |
Phase 3 | Recruiting |
| NCT07219407 | A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures (ClinicalTrials.gov ↗) Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy |
Phase 2 | Recruiting |
| NCT07046494 | Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder (ClinicalTrials.gov ↗) Bipolar 1 Disorder |
Phase 2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Epilepsy | 3 |
| Focal Epilepsy | 3 |
| Focal Seizure | 2 |
| Bipolar 1 Disorder | 1 |
| Refractory Focal Epilepsy | 1 |
| Seizure | 1 |
| Lead sponsor | Trials |
|---|---|
| Rapport Therapeutics Inc. | 4 |
| Register | RAP-219 trials |
|---|---|
| Clinical trials in USA | 4 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how RAP-219 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists RAP-219 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.